Equity Profile

TYRA

Tyra Biosciences, Inc.

Health CareBiotechnology$1.9B

May13Wed

Post-Earnings Recap

ReportedQ1-2026Pre-Market8:00 AM EDT

Tyra Biosciences Misses on EPS, Stock Up 3.79%

Metric	Actual	Expected	Surprise
EPS	$-0.64	$-0.59	-6.14%
Revenue	$0M	$0M	N/A

management commentary, guidance changes, and full analysis available with Pro.

Tyra Biosciences Misses on EPS, Stock Up 3.79%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.64	$-0.59	-6.14%
Revenue	$0M	$0M	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Tyra Biosciences reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock reacted positively, increasing by 3.79%. This could indicate that investors are looking beyond the EPS miss, possibly due to other factors not disclosed in the earnings call.

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$-0.59

Revenue

Although no revenue is expected this quarter, any updates on future revenue potential could be critical for investor confidence.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. As part of the health care sector, its advancements could significantly impact patient outcomes and the broader biotech landscape.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.57%

Avg Stock Reaction

+0.14%

Last Quarter Recap

In Q4-2025, Tyra reported an EPS of $-0.57, slightly missing analyst expectations. The stock reacted negatively, dropping 2.37% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Tyra to report a loss of $0.59 per share, consistent with its recent performance. Investors are closely watching for any signs of future revenue generation.

Bull Case

If Tyra can show progress in its clinical trials or partnerships that indicate future revenue, it could boost investor sentiment and stock price.

Bear Case

Continued losses without a clear path to revenue could lead to further declines in stock price, especially if the company fails to meet expectations.

Key Metrics to Watch

EPS

$-0.59

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$0M

Although no revenue is expected this quarter, any updates on future revenue potential could be critical for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements or updates can Tyra provide regarding its clinical trials?

Investors will be keen to understand the timeline and potential outcomes of these trials, as they could significantly impact future revenue.

Will there be any guidance on expected revenue generation in the upcoming quarters?

Clear guidance on future revenue could help alleviate concerns about ongoing losses and provide a roadmap for growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Tyra's potential for future revenue generation based on its clinical trial advancements, which could lead to a more favorable outlook than currently anticipated.

Supporting Evidence

The options market is pricing a significant move, indicating that investors expect more than just a typical earnings report.

Tyra's historical performance shows a tendency to surprise positively, suggesting that the consensus may be too conservative.

Key Risk

If Tyra provides strong updates on clinical trials, it could shift investor sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Tyra's ability to transition from losses to potential revenue generation.

Bull Confirmed If

Any indication of successful trial results or partnerships that suggest future revenue generation.

Bear Confirmed If

Continued losses without any guidance on future revenue or clinical progress.

Pre-Earnings Positioning

Options Market

Implied Move

±21.9%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant potential movement in the stock post-earnings, reflecting uncertainty among investors.

Options are pricing ±14.6% while TYRA has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

2.0%

30d HV

53.5%

Calls (600)P/C Ratio: 1.00Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 1 of 6 (17%)

This setup has occurred 30 times across Health Care in the last 2 years. 5 of 6 (83%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 3.6%, with a raw directional average of -2.0% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tyra beats expectations, history suggests a modest reaction, with an average 1-day move of -0.16%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

Should Tyra miss expectations, history suggests a potential decline of around 1.13%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial progress and timelines.
2Any guidance on expected revenue generation in the near future.
3Details on partnerships or collaborations that could lead to revenue.
4Management's outlook on the competitive landscape in biotechnology.
5Responses to analyst questions regarding cash burn and funding strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

RadNet, Inc.

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$-0.59

Revenue

Although no revenue is expected this quarter, any updates on future revenue potential could be critical for investor confidence.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.57%

Avg Stock Reaction

+0.14%

Last Quarter Recap

In Q4-2025, Tyra reported an EPS of $-0.57, slightly missing analyst expectations. The stock reacted negatively, dropping 2.37% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Tyra to report a loss of $0.59 per share, consistent with its recent performance. Investors are closely watching for any signs of future revenue generation.

Bull Case

If Tyra can show progress in its clinical trials or partnerships that indicate future revenue, it could boost investor sentiment and stock price.

Bear Case

Continued losses without a clear path to revenue could lead to further declines in stock price, especially if the company fails to meet expectations.

Key Metrics to Watch

EPS

$-0.59

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$0M

Although no revenue is expected this quarter, any updates on future revenue potential could be critical for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements or updates can Tyra provide regarding its clinical trials?

Investors will be keen to understand the timeline and potential outcomes of these trials, as they could significantly impact future revenue.

Will there be any guidance on expected revenue generation in the upcoming quarters?

Clear guidance on future revenue could help alleviate concerns about ongoing losses and provide a roadmap for growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Tyra's potential for future revenue generation based on its clinical trial advancements, which could lead to a more favorable outlook than currently anticipated.

Supporting Evidence

The options market is pricing a significant move, indicating that investors expect more than just a typical earnings report.

Tyra's historical performance shows a tendency to surprise positively, suggesting that the consensus may be too conservative.

Key Risk

If Tyra provides strong updates on clinical trials, it could shift investor sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Tyra's ability to transition from losses to potential revenue generation.

Bull Confirmed If

Any indication of successful trial results or partnerships that suggest future revenue generation.

Bear Confirmed If

Continued losses without any guidance on future revenue or clinical progress.

Pre-Earnings Positioning

Options Market

Implied Move

±21.9%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant potential movement in the stock post-earnings, reflecting uncertainty among investors.

Options are pricing ±14.6% while TYRA has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

2.0%

30d HV

53.5%

Calls (600)P/C Ratio: 1.00Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 1 of 6 (17%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tyra beats expectations, history suggests a modest reaction, with an average 1-day move of -0.16%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

Should Tyra miss expectations, history suggests a potential decline of around 1.13%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial progress and timelines.
2Any guidance on expected revenue generation in the near future.
3Details on partnerships or collaborations that could lead to revenue.
4Management's outlook on the competitive landscape in biotechnology.
5Responses to analyst questions regarding cash burn and funding strategies.